In vivo testing of a novel adjustable glaucoma drainage device.
- Villamarin A Swiss Federal Institute of Technology, Lausanne, Switzerland.
- Stergiopulos N Swiss Federal Institute of Technology, Lausanne, Switzerland.
- Bigler S Swiss Federal Institute of Technology, Lausanne, Switzerland.
- Mermoud A Glaucoma Center Montchoisi Clinic, Lausanne, Switzerland.
- Moulin A Jules Gonin Eyes Hospital, Lausanne, Switzerland.
- Roy S Swiss Federal Institute of Technology, Lausanne, Switzerland Glaucoma Center Montchoisi Clinic, Lausanne, Switzerland.
- 2014-10-16
Published in:
- Investigative ophthalmology & visual science. - 2014
aqueous humor
aqueous shunt
drainage device
filtering surgery
glaucoma drainage device
Animals
Anterior Chamber
Disease Models, Animal
Follow-Up Studies
Glaucoma Drainage Implants
Glaucoma, Open-Angle
Intraocular Pressure
Prosthesis Design
Prosthesis Implantation
Rabbits
Trabeculectomy
English
PURPOSE
We report on the in vivo testing of a novel noninvasively adjustable glaucoma drainage device (AGDD), which features an adjustable outflow resistance, and assess the safety and efficiency of this implant.
METHODS
Under general anesthesia, the AGDD was implanted on seven white New Zealand rabbits for a duration of 4 months under a scleral flap in a way analogous to the Ex-PRESS device and set in an operationally closed position. The IOP was measured on a regular basis on the operated and control eyes using a rebound tonometer. Once a month the AGDD was adjusted noninvasively from its fully closed to its fully open position and the resulting pressure drop was measured. The contralateral eye was not operated and served as control. After euthanization, the eyes were collected for histology evaluation.
RESULTS
The mean preoperative IOP was 11.1 ± 2.4 mm Hg. The IOP was significantly lower for the operated eye (6.8 ± 2 mm Hg) compared to the nonoperated eye (13.1 ± 1.6 mm Hg) during the first 8 days after surgery. When opening the AGDD from its fully closed to fully open position, the IOP dropped significantly from 11.2 ± 2.9 to 4.8 ± 0.9 mm Hg (P < 0.05).
CONCLUSIONS
Implanting the AGDD is a safe and uncomplicated surgical procedure. The fluidic resistance was noninvasively adjustable during the postoperative period with the AGDD between its fully closed and fully open positions.
We report on the in vivo testing of a novel noninvasively adjustable glaucoma drainage device (AGDD), which features an adjustable outflow resistance, and assess the safety and efficiency of this implant.
METHODS
Under general anesthesia, the AGDD was implanted on seven white New Zealand rabbits for a duration of 4 months under a scleral flap in a way analogous to the Ex-PRESS device and set in an operationally closed position. The IOP was measured on a regular basis on the operated and control eyes using a rebound tonometer. Once a month the AGDD was adjusted noninvasively from its fully closed to its fully open position and the resulting pressure drop was measured. The contralateral eye was not operated and served as control. After euthanization, the eyes were collected for histology evaluation.
RESULTS
The mean preoperative IOP was 11.1 ± 2.4 mm Hg. The IOP was significantly lower for the operated eye (6.8 ± 2 mm Hg) compared to the nonoperated eye (13.1 ± 1.6 mm Hg) during the first 8 days after surgery. When opening the AGDD from its fully closed to fully open position, the IOP dropped significantly from 11.2 ± 2.9 to 4.8 ± 0.9 mm Hg (P < 0.05).
CONCLUSIONS
Implanting the AGDD is a safe and uncomplicated surgical procedure. The fluidic resistance was noninvasively adjustable during the postoperative period with the AGDD between its fully closed and fully open positions.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1167/iovs.14-14563
- PMID 25316722
- Persistent URL
- https://sonar.ch/global/documents/231567
Statistics
Document views: 22
File downloads:
- Full-text: 0